Washington: The US’ National Institute of Health has said that India’s Bharat Biotech-developed Covaxin effectively neutralises both Alpha and Delta variants of COVID-19.
According to NIH, results of a couple of studies of blood serum from people who had taken the Covaxin jab suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2. The Alpha and Delta variants were first identified in the UK and India, respectively.
“The results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively,” the NIH was quoted as saying by news agency PTI.
“Meanwhile, unpublished interim results from the phase 3 trial indicate that the vaccine has 78 per cent efficacy against symptomatic disease, 100 per cent efficacy against severe COVID-19, including hospitalisation, and 70 per cent efficacy against asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19,” it said.
ALSO READ: Vaccine For Children: Covaxin May Be Approved By Sept, Says AIIMS Chief
Comments are closed.